Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
(2021) Leukemia — Vol. 35, n° 12, p. 3637 (2021)
Files
SekeresMALeukemia2021.pdf
Open Access - Adobe PDF
- 299.93 KB
Details
- Authors
Sekeres, Mikkael A 
- Abstract
- (en) Correction to: Leukemia 10.1038/s41375-021-01125-4, published online 22 January 2021. In Supplementary Table 2, the n numbers for the response-evaluable patients with higher-risk MDS were swapped for the pevonedistat + azacitidine arm and the azacitidine alone arm. Instead of n = 30 and n = 29 as originally published, these have now been corrected to n = 29 for pevonedistat + azacitidine and n = 30 for azacitidine. No changes were required to the response rate percentages as these were calculated using the correct denominators. The updated files are attached to this correction.
- Affiliations
Citations
Sekeres, M. A., Watts, J., Radinoff, A., Sangerman, M. A., Cerrano, M., Lopez, P. F., Zeidner, J. F., Campelo, M. D., Graux, C., Liesveld, J., Selleslag, D., Tzvetkov, N., Fram, R. J., Zhao, D., Bell, J., Friedlander, S., Faller, D. V., & Adès, L. (2021). Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia, 35(12), 3637. https://doi.org/10.1038/s41375-021-01473-1 (Original work published 2021)